Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. - Wikidata - wikimedia - TriplyDB

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

http://www.wikidata.org/entity/Q34436572

about

Selective gene silencing by viral delivery of short hairpin RNA Emerging role of non-coding RNA in neural plasticity, cognitive function, and neuropsychiatric disorders The promises and pitfalls of RNA-interference-based therapeutics Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations siRNA Delivery by Stimuli-Sensitive Nanocarriers Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives Delivery of siRNA to ovarian cancer cells using laser-activated carbon nanoparticles.In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes Silencing Viral Infection Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma Unexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNA siRNAs: potential therapeutic agents against hepatitis C virus Knocking down disease: a progress report on siRNA therapeutics MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality Current prospects for RNA interference-based therapies Progress toward in vivo use of siRNAs-II Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Cytokines as biomarkers of nanoparticle immunotoxicity Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6 Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes Lipid-based vectors for siRNA delivery Silencing disease genes in the laboratory and the clinic Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity.Chemical modification: the key to clinical application of RNA interference?A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.Designer siRNAs to overcome the challenges from the RNAi pathway.Applications of mass spectrometry to the study of siRNA.Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.Advances in Systemic siRNA Delivery Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications.Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9.Drug delivery-mediated control of RNA immunostimulation

P2860

Q21245112-3CD72E95-CF2D-450E-90C5-4B036FFA6F1B Q21558421-6FABA67D-F8C3-4790-90CA-66B25A340230 Q24657247-4D42C00D-035C-47E6-AE80-32DDB2315A6E Q24669624-B0BE5228-86BD-44E0-B59B-F3517BEA02AD Q26773183-EB8FF32D-E436-41AB-946F-4DAF5B62EB67 Q26781212-A0FF054D-B2F7-44D8-9EB5-AC9E44D16AEA Q26782089-98D9438C-C2BF-48F2-8F21-43AD3027E984 Q26852489-9E192E5A-213B-4BAF-A0BE-CCF2A1D3846F Q26859021-EC7EE6E9-2884-46CF-8B18-5447DAC81573 Q27335339-B438526B-7116-4853-B3BE-B5B21A17AD81 Q27468929-F5BA52F0-8346-4FE3-8487-35EA062182C8 Q27473399-CB1EF062-C96E-4E87-A643-F65AE04593A1 Q27488744-7CE8E12B-4036-4105-ABC2-F160371057F9 Q27666384-E05AF85C-99EC-49DA-8885-0DC449CF9C9B Q27694682-D2D2860A-A1DF-461F-9479-BF3B98EFD70C Q28082939-A0A9F061-B30D-40B7-9F66-7CE78B938ADB Q28115464-738DFE72-6608-4D33-9C0D-A63B27A76632 Q28235733-4D306E7E-7A23-4217-8341-3EB46E3BE39F Q28255877-43A00743-4201-4E2D-A00A-659D2D8F8EF4 Q28266775-ADF0E021-9AC6-4DE1-A14E-EE4BBD25F4B9 Q28383550-12C941AF-EEB4-4B31-A1CF-FD51EFAB6B55 Q28540216-7D541A05-DDD5-4EAA-94B3-280A671B5CCE Q28583617-D004AEF7-1AB6-43B5-9913-7EE8ABBAD15B Q28828356-E03FEED3-6542-4E6B-A0CC-58050DE6C42C Q29039090-C03DAB13-09F0-4590-8A1E-626527598607 Q30502702-E6DD0382-2502-439A-A556-83E75EEF5E29 Q30531035-9C51F93E-69D2-42F8-A1CD-510D6A2776E3 Q33268852-86205D11-6E2D-43C4-AE89-52DE357AFB2E Q33308712-3BB3C27E-E7FF-467D-815E-C44A652FCB57 Q33330928-C9136FD1-BDD7-4209-AD40-545E1A63128D Q33393397-45F12608-FF66-441D-9D10-09BE7BB1A2CD Q33505682-02057384-B402-45E4-B74A-D53E24CF94FA Q33536680-ABD7DE11-CFE7-446B-BE1F-CCDD1D6EDFEB Q33554206-1EAD83BC-95B3-438F-B229-DD0D738E8DB6 Q33572902-C1303852-4182-43D5-B214-AFC7C9664D72 Q33608651-E53AB2D1-8322-4117-A58E-4F58805AE303 Q33613316-37D24F38-0E8A-4D76-9CAD-D4F88481FB81 Q33668095-57370E40-E89C-4CCF-95E5-6195E21C4999 Q33713259-AA0E27CA-9D17-4123-94F8-0C279546FBEF Q33713938-E05865BA-91BF-4F07-964D-7FCD1DF4229E

P2860

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

http://www.wikidata.org/entity/Q34436572

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@ast

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@en

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@nl

type

label

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@ast

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@en

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@nl

prefLabel

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@ast

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@en

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@nl

P1433

Q34436572-C3EC99F3-9FEA-4818-81D0-C66A53E7234C

P1476

Q34436572-9A9F1E67-5695-4E8F-AED1-0BFD2DF572E1

P2093

Q34436572-0A32FECB-EC29-412A-96DE-22A96B6DCE35

Q34436572-142E2FDD-50E8-4979-96CF-614F13125A28

Q34436572-451165B3-D978-405A-A9B4-FA34846DB64F

Q34436572-4F014F9A-67D2-4C78-A97E-7F70639C9631

Q34436572-556B9F48-2503-4CF6-9716-D162FC02A09E

Q34436572-6EACC604-CB41-45BC-8ED1-3BC6EAF90CE3

Q34436572-723B6051-A75D-4DF8-844F-840B3F3AC6B2

Q34436572-A3080505-D24D-4809-B315-FCD48BD4FB6E

Q34436572-A84665DF-91E3-42D3-AC29-BA60BE4CF6D3

Q34436572-B0EECB59-185E-472E-B0B3-9AB833ED28C5

P2860

Q34436572-03E6D9A1-5CB7-41C8-B353-B06340E94604

Q34436572-1238004C-1FB4-4120-BC6D-15ED32D1C06F

Q34436572-12F8F532-D000-4E27-8AAB-1EAA2C1492A0

Q34436572-2D7FADED-DB7E-4728-A55F-C4C8E221A309

Q34436572-2EE3A1F7-7769-42C0-A4DE-2411E15083EC

Q34436572-451A8A05-4E4C-4FBF-85A5-44541663C5B9

Q34436572-49EF3B89-1E66-4C7F-9788-8B2652077599

Q34436572-54353A64-6FBF-482A-9908-65693F3D4D52

Q34436572-6E4A08D5-9270-4801-8C59-64F1F3BF3D5B

Q34436572-B808E734-506D-48EC-A9A9-082C5DFA93C2

P2888

Q34436572-CB423956-1C7F-4721-A2C3-25470CF733BD

P304

Q34436572-D51C7586-0F25-42F8-B94E-78EB29ADA4BE

P31

Q34436572-29EB5412-239A-45B5-8900-B93EAD65C0A8

P356

Q34436572-7E262E01-6FD6-43A7-84DB-9C27CEC68EE4

P433

Q34436572-BD1CAED9-41F3-4ADC-9473-18B32B9DB4B6

P478

Q34436572-D7B1B8DB-4700-422E-B0EB-CACCE32F5E6A

P577

Q34436572-0A72FE8D-87B0-4253-9C83-A7001BEB80AD

P5875

Q34436572-1863F7A6-A386-48E8-88D9-4248958F370E

P698

Q34436572-A7CF74A2-58E7-4531-B8EA-81CF02EF6BEE

P356

P1433

Nature Biotechnology

P1476

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

@en

P2093

Adam Judge

http://www.w3.org/2001/XMLSchema#string

Barry Polisky

http://www.w3.org/2001/XMLSchema#string

Chandra Vargeese

http://www.w3.org/2001/XMLSchema#string

Chris S Shaffer

http://www.w3.org/2001/XMLSchema#string

David V Morrissey

http://www.w3.org/2001/XMLSchema#string

Ian MacLachlan

http://www.w3.org/2001/XMLSchema#string

Jennifer A Lockridge

http://www.w3.org/2001/XMLSchema#string

Karin Blanchard

http://www.w3.org/2001/XMLSchema#string

Keith Bowman

http://www.w3.org/2001/XMLSchema#string

Kimberly Hartsough

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Antiviral actions of interferons

Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection

In vivo activity of nuclease-resistant siRNAs

Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.

Synthesis, deprotection, analysis and purification of RNA and ribozymes

Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase.

Stabilized plasmid-lipid particles: construction and characterization.

A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA.

siRNA function in RNAi: a chemical modification analysis.

P2888

P304

1002-1007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT1122

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7704869

http://www.w3.org/2001/XMLSchema#string

P698

16041363

http://www.w3.org/2001/XMLSchema#string